Press Releases
GlaxoSmithKline presents positive data for Anoro Ellipta in COPD patients who remained symptomatic on tiotropium
GlaxoSmithKline and Innoviva Inc announced results from data presented at the American Thoracic Society (ATS) 2016 International Conference investigating the efficacy and safety of...
Press Releases
Merck and Pfizer to Present Avelumab Data in Seven Different Cancers at ASCO Annual Meeting
14 avelumab abstracts at ASCO 2016 highlight significant progress being made by the collaboration between Merck KGaA, Darmstadt, Germany, and Pfizer Two oral...
Press Releases
AstraZeneca reports the positive Top-Line Results from the Benralizumab Phase III Programme in Severe Asthma
Kyowa Hakko Kirin Co Ltd announced that AstraZeneca obtained the positive top-line results that benralizumab, a potential new medicine and anti-eosinophil monoclonal antibody, was...
Press Releases
FDA approves For Eisais Anticancer Agent Lenvima In Combination With Everolimus as Treatment For advanced Renal Cell Carcinoma
Eisai Co Ltd announced that its U.S. subsidiary Eisai Inc. has received approval from the U.S. Food and Drug Administration (FDA) for an additional...
Press Releases
AstraZeneca reports positive results from benralizumab phase III programme
AstraZeneca announced that benralizumab, a potential new medicine and anti-eosinophil monoclonal antibody, was well tolerated and achieved the primary endpoint in two pivotal Phase...
News
Novartis Foundation and partners launch of the of the Ho Chi Minh City Communities for Healthy Hearts Program in Vietnam
Ho Chi Minh City Communities for Healthy Hearts Program is the second innovative healthcare model for hypertension pioneered by the Novartis Foundation Screening...
Press Releases
AstraZeneca announces positive results from benralizumab phase III programme in severe asthma
AstraZeneca announced that benralizumab, a potential new medicine and anti-eosinophil monoclonal antibody, was well tolerated and achieved the primary endpoint in two pivotal Phase...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read